Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

7 evidence topics · 10 sources

Summary: limitations of current therapies

A review states that the highest response to medical therapies “ranges from 30% to 60% in clinical trials”, and another review states that “10-20% of patients still require proctocolectomy for medically refractory disease.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”; the ECCO 2026 guideline reports that 40% of patients on vedolizumab maintenance lose response. Among 3,562 patients initiating advanced therapy, 47.8% remained steroid-free after 12 months, and mean UC-related costs in the 12 months after initiation were $42,579. The two oral classes carry restrictions: the tofacitinib label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and both U.S. JAK inhibitor labels indicate them in ulcerative colitis after an inadequate response or intolerance to one or more TNF blockers (for upadacitinib, after at least one approved systemic therapy when TNF blockers are clinically inadvisable); the S1P receptor modulators require pre-treatment assessments, and the ACG 2025 guideline states that significant cardiovascular disease and cardiac conduction defects, among other conditions, contraindicate ozanimod. Biologics require injections or intravenous infusions, which Abivax describes as resulting in “patient inconvenience and burden”.